The possibilities of using combination therapy in patients with dyscirculatory encephalopathy

Abstract.The article presents the results of a clinical study on the efficiency and tolerability of the combined use of drugs Neurocytin and Latren, solutions in comparison with the drug Neurocytin, solution, produced by Yuria Pharm Ltd. in patients with stage II arterial hypertension (AH) and atherosclerosis.
Studies were conducted in 92 patients of both sexes, aged from 52 to 76 years old. The patients were divided into 3 groups: 30 patients received Neurocytin 100 ml/day and Latren 200 ml/day intravenosus (main group), 30 patients received Neurocytin 100 ml/day (comparison group). The control group consisted of 32 patients with DE II stage, who received only basic therapy. The course of drug use was 10 days.
The efficiency and safety of drugs under study were evaluated on the basis of clinical, neurological, psychodiagnostical, laboratory and statistical methods.
The results of the study made it possible to conclude that the combined use of the drugs Neurocytin and Latren has a more expressed (compared to Neurocytin) therapeutic effects on the clinical and neurological symptoms, cognitive functions, asthenic symptoms. The course of treatment with two drugs did not reveal any side effects or intolerance in patients.
Keywords: dyscirculatory encephalopathy, treatment, combination therapy, cognitive impairment.

15 April, 2019

Authors:

T.S. Mishchenko V.M. Mishchenko В.Г. Деревецька

Products:

Latren®

Learn more

Uncategorized

Vascular neurological complications in patients with COVID-19

Uncategorized

Astenic syndrome in a post-covid-19 patient (review and own experience)

Among the symptoms and syndromes that dominate the clinical picture of postcoid syndrome (POST-COVID-19), the signs of asthenia, increased fatigue, excessive exhaustion during normal daily activities, which form asthenic syndrome, are highlighted. For the treatment of postcoid asthenic syndrome, a combination of pathogenetically justified agents has been proposed: podaravone (Xavron), a mixture of L-arginine and...
Uncategorized

” Long-haulers “: patients with post-covid syndrome in routine clinical practice

At the beginning of the COVID 19 pandemic, SARS-CoV 2 disease was thought to be transient (like most respiratory viral infections). The World Health Organization later reported that the duration of a new coronavirus disease from the onset of the first symptoms to mild clinical recovery is ≈2 weeks, and in severe or moderate cases,...
Uncategorized

The importance of non-motor symptoms in the clinical picture of motor neuron disease

Non-motor symptoms are an obligate sign of motor neuron disease and can often serve as a rather sensitive indicator of the general functional state of ALS patients. Gastrointestinal disorders, weight loss, pain, sweating and anxiety prevail in the structure of non-motor symptoms in ALS patients. The presence of non-motor symptoms in patients indicates the multisystemic...
Uncategorized

Modern possibilities of infusion therapy in patients with diabetic ketoacidosis

Summary. The mechanisms of development and clinical manifestations of diabetic ketoacidosis (DKA) are analyzed in the article, the infusion therapy program is presented, the prospects of the use of xylitol-based infusions in the treatment of DKA are discussed. The authors also presented their own experience with the use of Xylat solution. It has been shown...
Uncategorized

Japanese experience in the treatment of patients with acute ischemic stroke. Interview with Professor Yukito Shinohara